Akebia Therapeutics receives Nasdaq deficiency notice over minimum bid price violation

• Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026, for breaching the minimum bid price requirement.
• Its common stock closed below $1.00 for 30 consecutive business days; the notice has no immediate effect on its listing.
• The initial 180-day compliance period ends April 19, 2027; compliance requires closing bids of at least $1.00 for 10 consecutive business days.
• A conditional 180-day extension requires meeting other listing standards and written intent to cure the deficiency through a reverse stock split if necessary.
• Failure to qualify for an extension or restore compliance by its end would trigger a delisting notice, subject to appeal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001517022-26-000075), on October 23, 2026, and is solely responsible for the information contained therein.